ARS Pharmaceuticals, Inc. Net Cash Provided by (Used in) Continuing Operations
ARS Pharmaceuticals, Inc. (SPRY) reported Net Cash Provided by (Used in) Continuing Operations of -$50.82 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-02.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:NetCashProvidedByUsedInContinuingOperations · last filed 2022-11-02
- ARS Pharmaceuticals, Inc. net cash provided by (used in) continuing operations for the quarter ending 2022-09-30 was -$15.47M.
- ARS Pharmaceuticals, Inc. net cash provided by (used in) continuing operations for the quarter ending 2022-06-30 was -$15.30M.
- ARS Pharmaceuticals, Inc. net cash provided by (used in) continuing operations for the quarter ending 2022-03-31 was -$20.06M.
- ARS Pharmaceuticals, Inc. net cash provided by (used in) continuing operations for the quarter ending 2021-12-31 was -$46.72M, a 119.14% decline year-over-year.
- ARS Pharmaceuticals, Inc. net cash provided by (used in) continuing operations for fiscal 2021 was -$132.62M, a 135.24% decline from fiscal 2020.
- ARS Pharmaceuticals, Inc. net cash provided by (used in) continuing operations for fiscal 2020 was $376.39M.
| Period end | Net Cash Provided by (Used in) Continuing Operations 3 month | Net Cash Provided by (Used in) Continuing Operations 6 month | Net Cash Provided by (Used in) Continuing Operations 9 month | Net Cash Provided by (Used in) Continuing Operations 12 month |
|---|---|---|---|---|
| 2022-09-30 | -$15.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$30.77M derived: sum of 2 quarters · filed 2022-11-02 | -$50.82M 10-Q · filed 2022-11-02 | -$97.54M derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-06-30 | -$15.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$35.35M 10-Q · filed 2022-08-11 | -$82.07M derived: sum of 3 quarters · filed 2022-08-11 | -$141.10M derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-03-31 | -$20.06M 10-Q · filed 2022-05-12 | -$66.77M derived: sum of 2 quarters · filed 2022-05-12 | -$125.80M derived: sum of 3 quarters · filed 2022-11-02 | -$140.32M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-12-31 | -$46.72M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$105.74M derived: sum of 2 quarters · filed 2022-11-02 | -$120.26M derived: sum of 3 quarters · filed 2022-11-02 | -$132.62M 10-K · filed 2022-03-31 |
| 2021-09-30 | -$59.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$73.55M derived: sum of 2 quarters · filed 2022-11-02 | -$85.91M 10-Q · filed 2022-11-02 | $158.14M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | -$14.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$26.88M 10-Q · filed 2022-08-11 | $217.17M derived: sum of 3 quarters · filed 2022-08-11 | $329.37M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$12.36M 10-Q · filed 2022-05-12 | $231.69M derived: sum of 2 quarters · filed 2022-05-12 | $343.89M derived: sum of 3 quarters · filed 2022-05-12 | $350.38M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $244.05M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $356.25M derived: sum of 2 quarters · filed 2022-03-31 | $362.74M derived: sum of 3 quarters · filed 2022-03-31 | $376.39M 10-K · filed 2022-03-31 |
| 2020-09-30 | $112.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $118.69M derived: sum of 2 quarters · filed 2021-11-10 | $132.34M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $6.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $20.14M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $13.65M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |